Pharmaceutical - USA, Allergan

Filter

Current filters:

USAAllergan

Popular Filters

Allergan attacks Valeant’s financial results

Allergan attacks Valeant’s financial results

06-08-2014

US Botox maker Allergan, the subject of a hostile $53 billion takeover attempt by Canada’s Valeant…

AllerganBusiness FinanceCanadaFinancialMergers & AcquisitionsPharmaceuticalUSAValeant PharmaceuticalsValeant Pharmaceuticals International

Allergan sues Valeant and Pershing Square, alleging insider trading

Allergan sues Valeant and Pershing Square, alleging insider trading

02-08-2014

US Botox maker Allergan, the subject of a hostile $53 billion takeover attempt by Canada’s Valeant…

AllerganBusiness FinanceLegalMergers & AcquisitionsPharmaceuticalUSAValeant Pharmaceuticals International

Allergan reports strong 2nd-qtr figures but still plan to cut 1,500 jobs worldwide

Allergan reports strong 2nd-qtr figures but still plan to cut 1,500 jobs worldwide

21-07-2014

Botox maker Allergan has reported its second quarter operating results while also announcing that it…

AllerganAllerganBotoxFinancialPharmaceuticalUSA

US FDA delays Allergan’s Semprana decision, approves Ozurdex

US FDA delays Allergan’s Semprana decision, approves Ozurdex

01-07-2014

US drugmaker Allergan, the subject of a hostile $53 billion takeover pursuit by Canada’s Valeant Pharmaceuticals…

AllerganBimatoprost Ophthalmic Solution 0.03% for GlaLevadexNeurologicalOphthalmicsOzurdexPharmaceuticalRegulationResearchSempranaUSA

Allergan rejects Valeant’s latest bid

Allergan rejects Valeant’s latest bid

24-06-2014

Botox maker Allergan has announced that its Board of Directors has unanimously determined that Valeant…

AllerganBusiness FinanceBusiness FinanceEconomicsFinanceMergers & AcquisitionsPharmaceuticalStock marketUSAValeant Pharmaceuticals

Allergan faces law suit alleging payment of kickbacks to optometrists to prescribe Restasis

Allergan faces law suit alleging payment of kickbacks to optometrists to prescribe Restasis

14-02-2014

US drugmaker Allergan (NYSE: AGN) is the subject of legal action after allegations that it paid kickbacks…

AllerganLegalOphthalmicsPharmaceuticalRestasisUSA

Allergan closes $65 million deal with Medytox

Allergan closes $65 million deal with Medytox

09-01-2014

This week US drugmaker Allergan (NYSE: AGN) announced that it has closed a $65 million license agreement…

AllerganAsia-PacificBotoxDermatologicalsLicensingMedytoxPharmaceuticalRegulationUKUSA

Back to top